everolimus — CareFirst (Caremark)
Neuroendocrine tumors of the gastrointestinal tract, lung, and thymus (carcinoid tumors)
Initial criteria
- Used for treatment of specified neuroendocrine tumors
Reauthorization criteria
- Continuation may be approved when there is no evidence of unacceptable toxicity or disease progression
Approval duration
12 months